174 related articles for article (PubMed ID: 11356103)
21. Synthesis of new 4-heteroaryl-2-phenylquinolines and their pharmacological activity as NK-2/NK-3 receptor ligands.
Borioni A; Mustazza C; Sestili I; Sbraccia M; Turchetto L; Del Giudice MR
Arch Pharm (Weinheim); 2007 Jan; 340(1):17-25. PubMed ID: 17206605
[TBL] [Abstract][Full Text] [Related]
22. Contribution of tachykinin receptor subtypes to micturition reflex in guinea pigs.
Yamamoto T; Hanioka N; Maeda Y; Imazumi K; Hamada K; Matsuo M; Manda T; Mutoh S
Eur J Pharmacol; 2003 Sep; 477(3):253-9. PubMed ID: 14522364
[TBL] [Abstract][Full Text] [Related]
23. Potency and selectivity of the tachykinin NK3 receptor antagonist SR 142801.
Beaujouan JC; Saffroy M; Torrens Y; Glowinski J
Eur J Pharmacol; 1997 Jan; 319(2-3):307-16. PubMed ID: 9042606
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo characterization of NK3 receptors in the rabbit eye by use of selective non-peptide NK3 receptor antagonists.
Medhurst AD; Hay DW; Parsons AA; Martin LD; Griswold DE
Br J Pharmacol; 1997 Oct; 122(3):469-76. PubMed ID: 9351503
[TBL] [Abstract][Full Text] [Related]
25. Multifaceted approach to determine the antagonist molecular mechanism and interaction of ibodutant ([1-(2-phenyl-1R-[[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl]-ethylcarbamoyl)-cyclopentyl]-amide) at the human tachykinin NK2 receptor.
Meini S; Bellucci F; Catalani C; Cucchi P; Giolitti A; Santicioli P; Giuliani S
J Pharmacol Exp Ther; 2009 May; 329(2):486-95. PubMed ID: 19218528
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of novel fluoro and iodo quinoline carboxamides as potential ligands of NK-3 receptors for in vivo imaging studies.
Bennacef I; Tymciu S; Dhilly M; Lasne MC; Debruyne D; Perrio C; Barré L
Bioorg Med Chem; 2004 Aug; 12(16):4533-41. PubMed ID: 15265501
[TBL] [Abstract][Full Text] [Related]
27. The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.
Deschamps K; Couture R
Br J Pharmacol; 2005 Jul; 145(6):712-27. PubMed ID: 15895109
[TBL] [Abstract][Full Text] [Related]
28. Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3.
Leffler A; Ahlstedt I; Engberg S; Svensson A; Billger M; Oberg L; Bjursell MK; Lindström E; von Mentzer B
Biochem Pharmacol; 2009 May; 77(9):1522-30. PubMed ID: 19426690
[TBL] [Abstract][Full Text] [Related]
29. Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.
Geldenhuys WJ; Kuzenko SR; Simmons MA
J Med Chem; 2010 Nov; 53(22):8080-8. PubMed ID: 21047106
[TBL] [Abstract][Full Text] [Related]
30. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
31. Neurokinin receptor antagonism: a patent review (2014-present).
Muñoz M; Coveñas R
Expert Opin Ther Pat; 2020 Jul; 30(7):527-539. PubMed ID: 32401556
[TBL] [Abstract][Full Text] [Related]
32. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
34. Distribution and pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors in the central nervous system of the rhesus monkey.
Nagano M; Saitow F; Haneda E; Konishi S; Hayashi M; Suzuki H
Br J Pharmacol; 2006 Feb; 147(3):316-23. PubMed ID: 16331282
[TBL] [Abstract][Full Text] [Related]
35. Attenuation of the gerbil writhing response by mu-, kappa- and delta-opioids, and NK-1, -2 and -3 receptor antagonists.
Gallantine EL; Meert TF
Pharmacol Biochem Behav; 2004 Sep; 79(1):125-35. PubMed ID: 15388292
[TBL] [Abstract][Full Text] [Related]
36. Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
Giolitti A; Altamura M; Bellucci F; Giannotti D; Meini S; Patacchini R; Rotondaro L; Zappitelli S; Maggi CA
J Med Chem; 2002 Aug; 45(16):3418-29. PubMed ID: 12139452
[TBL] [Abstract][Full Text] [Related]
37. The non-peptide tachykinin NK2 receptor antagonist SR 48968 interacts with human, but not rat, cloned tachykinin NK3 receptors.
Chung FZ; Wu LH; Vartanian MA; Watling KJ; Guard S; Woodruff GN; Oxender DL
Biochem Biophys Res Commun; 1994 Feb; 198(3):967-72. PubMed ID: 8117304
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of a novel class of non-peptide NK-2 receptor ligand, derived from 1-phenyl-3-pyrrol-1-ylindan-2-carboxamides.
Guillon J; Dallemagne P; Léger JM; Sopkova J; Bovy PR; Jarry C; Rault S
Bioorg Med Chem; 2002 Apr; 10(4):1043-50. PubMed ID: 11836113
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological evaluation of alpha and beta human tachykinin NK(2) receptor splice variants expressed in CHO cells.
Bellucci F; Meini S; Catalioto RM; Catalani C; Giuliani S; Quartara L; Giolitti A; Faiella A; Rotondaro L; Candenas ML; Pinto FM; Maggi CA
Eur J Pharmacol; 2004 Sep; 499(3):229-38. PubMed ID: 15381044
[TBL] [Abstract][Full Text] [Related]
40. Neurokinin receptors in the guinea pig ileum.
Nguyen-Le XK; Nguyen QT; Gobeil F; Jukic D; Chrétien L; Regoli D
Pharmacology; 1996 Jan; 52(1):35-45. PubMed ID: 8966201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
